<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">arthyper</journal-id><journal-title-group><journal-title xml:lang="ru">Артериальная гипертензия</journal-title><trans-title-group xml:lang="en"><trans-title>"Arterial’naya Gipertenziya" ("Arterial Hypertension")</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1607-419X</issn><issn pub-type="epub">2411-8524</issn><publisher><publisher-name>Antihypertensive League</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/1607-419X-2018-24-1-101-107</article-id><article-id custom-type="elpub" pub-id-type="custom">arthyper-766</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЛЕКЦИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>LECTURE</subject></subj-group></article-categories><title-group><article-title>ЗНАЧЕНИЕ СЫВОРОТОЧНЫХ БИОМАРКЕРОВ В ПРОГНОЗИРОВАНИИ РАЗВИТИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ И СМЕРТНОСТИ</article-title><trans-title-group xml:lang="en"><trans-title>SERUM BIOMARKERS IN HEART FAILURE AND CARDIOVASCULAR MORTALITY PREDICTION</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хамитова</surname><given-names>А. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Khamitova</surname><given-names>A. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Хамитова Айсылу Фаризовна — аспирант второго года очного обучения кафедры пропедевтики внутренних болезней.</p><p> </p></bio><bio xml:lang="en"><p>Aysilu F. Khamitova, MD, PhD Student, Department of Propaedeutics of Internal Diseases.</p><p>Ufa. </p></bio><email xlink:type="simple">musina.aisylu@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дождев</surname><given-names>С. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Dozhdev</surname><given-names>S. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дождев Сергей Сергеевич — студент V курса.</p><p> </p></bio><bio xml:lang="en"><p>Sergey S. Dozhdev, 5-year Student.</p><p>Ufa. </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Загидуллин</surname><given-names>Ш. З.</given-names></name><name name-style="western" xml:lang="en"><surname>Zagidullin</surname><given-names>S. Z.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Загидуллин Шамиль Зарифович — доктор медицинских наук, профессор кафедры пропедевтики внутренних болезней.</p><p> </p></bio><bio xml:lang="en"><p>Shamil’ Z. Zagidullin, MD, PhD, DSc, Professor, Department of Propaedeutics of Internal Diseases.</p><p>Ufa. </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ионин</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Ionin</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ионин Валерий Александрович — кандидат медицинских наук, ассистент кафедры факультетской терапии с курсом эндокринологии и функциональной диагностики имени Г. Ф. Ланга.</p><p> </p></bio><bio xml:lang="en"><p>Valeriy A. Ionin, MD, PhD, Assistant, Department of Internal Diseases.</p><p>St. Petersburg.</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гареева</surname><given-names>Д. Ф.</given-names></name><name name-style="western" xml:lang="en"><surname>Gareeva</surname><given-names>D. F.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гареева Диана Фирдависовна — ассистент кафедры пропедевтики внутренних болезней.</p><p> </p></bio><bio xml:lang="en"><p>Diana F. Gareeva, MD, Assistant, Department of Propaedeutics of Internal Diseases.</p><p>Ufa. </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Загидуллин</surname><given-names>Н. Ш.</given-names></name><name name-style="western" xml:lang="en"><surname>Zagidullin</surname><given-names>N. Sh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Загидуллин Науфаль Шамилевич — доктор медицинских наук, доцент кафедры пропедевтики внутренних болезней.</p><p> </p></bio><bio xml:lang="en"><p>Naufal’ Sh. Zagidullin, MD, PhD, DSc, Associate Professor, Department of Propaedeutics of Internal Diseases.</p><p>Ufa. </p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution> Федеральное государственное бюджетное образовательное  учреждение высшего образования «Башкирский  государственный медицинский университет» Министерства  здравоохранения Российской Федерации.</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Bashkir State Medical University.</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Федеральное государственное образовательное учреждение  высшего образования «Первый Санкт-Петербургский  государственный медицинский университет имени академика  И. П. Павлова» Министерства здравоохранения Российской  Федерации.</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pavlov First State Medical University of St. Petersburg.</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>12</day><month>03</month><year>2018</year></pub-date><volume>24</volume><issue>1</issue><fpage>101</fpage><lpage>107</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Хамитова А.Ф., Дождев С.С., Загидуллин Ш.З., Ионин В.А., Гареева Д.Ф., Загидуллин Н.Ш., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Хамитова А.Ф., Дождев С.С., Загидуллин Ш.З., Ионин В.А., Гареева Д.Ф., Загидуллин Н.Ш.</copyright-holder><copyright-holder xml:lang="en">Khamitova A.F., Dozhdev S.S., Zagidullin S.Z., Ionin V.A., Gareeva D.F., Zagidullin N.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://htn.almazovcentre.ru/jour/article/view/766">https://htn.almazovcentre.ru/jour/article/view/766</self-uri><abstract><p>Хроническая сердечная недостаточность (ХСН) является одной из важнейших клинических проблем современной медицины, что связано с ее широкой распространенностью, низким качеством жизни больных, плохим прогнозом и высокой смертностью. ХСН является одним из последних звеньев кардиоваскулярного континуума, который начинается с факторов риска артериальной гипертензии (АГ) и приводит к развитию ишемической болезни сердца, инфаркта миокарда с последующим снижением насосной функции сердца. Ранняя диагностика АГ и оценка риска позволят вовремя воздействовать на звенья цепи кардиоваскулярного континуума. В последнее время в диагностике сердечной недостаточности и кардиоваскулярных событий огромное значение имеют сывороточные биомаркеры, которые отражают различные патофизиологические аспекты функционирования организма. В частности, выделяют биомаркеры апоптоза (фактор некроза опухоли альфа, Fas), ремоделирования внеклеточного матрикса (металлопротеиназы), воспаления и фиброза (галектин-3, ST2, трансформирующий фактор роста бета 1). В обзоре представлена краткая характеристика вышеуказанных биомаркеров и их влияний на развитие ХСН и сердечно-сосудистых событий.</p></abstract><trans-abstract xml:lang="en"><p>Coronary heart disease is one of the most important clinical problems of modern medicine, which is associated with its high prevalence, low quality of life, poor prognosis and high mortality. Chronic heart failure (CHF) is one of the cardiovascular continuum endpoints, which starts from the risk factors of arterial hypertension (HTN) and leads to the development of atherosclerosis, myocardial infarction and subsequent reduction of the pumping function of the heart. According to the Framingham study, systolic blood pressure &gt; 140 mm Hg is associated with a 4-fold increase in the risk of CHF and the normalization of blood pressure allows a 50 % reduction in the risk of CHF. Early diagnosis of HTN and risk assessment will allow to interrupt the cardiovascular continuum. Recently the serum biomarkers have been recognized as important toll for the diagnosis of heart failure and cardiovascular events. They reflect various pathophysiological aspects. In particular, the following biomarkers are produced in CHF: biomarkers of apoptosis (tumor necrosis factor α, Fas), remodeling of extracellular matrix metalloproteinase, inflammation and fibrosis (galectin-3, ST2, transforming growth factor beta 1). The review presents a brief description of the above biomarkers and their effects on the development of CHF and cardiovascular events.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>сердечная недостаточность</kwd><kwd>сердечно-сосудистые события</kwd><kwd>сывороточные биомаркеры</kwd></kwd-group><kwd-group xml:lang="en"><kwd>heart failure</kwd><kwd>cardiovascular events</kwd><kwd>serum biomarkers</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Хафизов Р. Р., Загидуллин Б. И., Загидуллин Н. Ш., Травникова Е. О., Загидуллин Ш. З. Перспективы применения «новых» биомаркеров в диагностике острого коронарного синдрома. Практическая медицина. 2012;5(60):89–92. [Haphyzov RR, Zagidullin BI, Zagidullin NSh, Travnokova EO, Zagidullin ShZ. Perspectives of use of “new” biomarkers in diagnostics of acute coronary syndrome. Prakticheskaya Meditsina = Practical Medicine. 2012;5(60):89–92. In Russian].</mixed-citation><mixed-citation xml:lang="en">Хафизов Р. Р., Загидуллин Б. И., Загидуллин Н. Ш., Травникова Е. О., Загидуллин Ш. З. Перспективы применения «новых» биомаркеров в диагностике острого коронарного синдрома. Практическая медицина. 2012;5(60):89–92. [Haphyzov RR, Zagidullin BI, Zagidullin NSh, Travnokova EO, Zagidullin ShZ. Perspectives of use of “new” biomarkers in diagnostics of acute coronary syndrome. Prakticheskaya Meditsina = Practical Medicine. 2012;5(60):89–92. In Russian].</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Медведева Е. А., Суркова Е. А., Лимарева Л. В., Щукин Ю. В. Молекулярные биомаркеры в диагностике, стратификации риска и прогнозировании сердечной недостаточности. Российский кардиологический журнал. 2016;8(136):86– 91. [Medvedeva EA, Surkova EA, Limareva LV, Shchukin YuV, Molecular biomarkers for diagnostics, risk stratification and prediction of chronic heart failure. Russian Journal of Cardiology. 2016;8(136):86–91. In Russian].</mixed-citation><mixed-citation xml:lang="en">Медведева Е. А., Суркова Е. А., Лимарева Л. В., Щукин Ю. В. Молекулярные биомаркеры в диагностике, стратификации риска и прогнозировании сердечной недостаточности. Российский кардиологический журнал. 2016;8(136):86– 91. [Medvedeva EA, Surkova EA, Limareva LV, Shchukin YuV, Molecular biomarkers for diagnostics, risk stratification and prediction of chronic heart failure. Russian Journal of Cardiology. 2016;8(136):86–91. In Russian].</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity. 2000;12(6):611–620.</mixed-citation><mixed-citation xml:lang="en">Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity. 2000;12(6):611–620.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Abbate A, Biondi-Zoccai GG, Bussani R Dobrina A, Camilot D, Feroce F, Rossiello et al. Increased myocardial apoptosis in patients with unfavorable left ventricular remodeling and early symptomatic postinfarction heart failure. J Am Coll Cardiol. 2003;41(5):753–760.</mixed-citation><mixed-citation xml:lang="en">Abbate A, Biondi-Zoccai GG, Bussani R Dobrina A, Camilot D, Feroce F, Rossiello et al. Increased myocardial apoptosis in patients with unfavorable left ventricular remodeling and early symptomatic postinfarction heart failure. J Am Coll Cardiol. 2003;41(5):753–760.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Secchiero P, Corallini F, Ceconi C, Parrinello G, Volpato S, Ferrari R, Zauli G. Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction. PLoS One. 2009;4(2): e4442. doi:10.1371/journal.pone.0004442. Epub 2009 Feb 16</mixed-citation><mixed-citation xml:lang="en">Secchiero P, Corallini F, Ceconi C, Parrinello G, Volpato S, Ferrari R, Zauli G. Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction. PLoS One. 2009;4(2): e4442. doi:10.1371/journal.pone.0004442. Epub 2009 Feb 16</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Osmancik P, Teringova E, Tousek P, Paulu P, Widimsky P. Prognostic value of TNF-related apoptosis inducing ligand (TRAIL) in acute coronary syndrome patients. PLoS One. 2013;8(2): e53860.</mixed-citation><mixed-citation xml:lang="en">Osmancik P, Teringova E, Tousek P, Paulu P, Widimsky P. Prognostic value of TNF-related apoptosis inducing ligand (TRAIL) in acute coronary syndrome patients. PLoS One. 2013;8(2): e53860.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ohtsuka T, Hamada M, Sasaki O, Suzuki M, Hara Y, Shigematsu Y et al. Clinical implications of circulating soluble Fas and Fas ligand in patients with acute myocardial infarction. Coron Artery Dis. 1999;10(4):221–225.</mixed-citation><mixed-citation xml:lang="en">Ohtsuka T, Hamada M, Sasaki O, Suzuki M, Hara Y, Shigematsu Y et al. Clinical implications of circulating soluble Fas and Fas ligand in patients with acute myocardial infarction. Coron Artery Dis. 1999;10(4):221–225.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Nilsson L, Szymanowski A, Swahn E, Jonasson L. Soluble TNF receptors are associated with infarct size and ventricular dysfunction in ST-elevation myocardial infarction. PLoS One. 2013;8(2): e55477.</mixed-citation><mixed-citation xml:lang="en">Nilsson L, Szymanowski A, Swahn E, Jonasson L. Soluble TNF receptors are associated with infarct size and ventricular dysfunction in ST-elevation myocardial infarction. PLoS One. 2013;8(2): e55477.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kawakami H, Shigematsu Y, Ohtsuka T, Okayama H, Hayashi Y, Hara Y et al. Increased circulating soluble form of Fas in patients with dilated cardiomyopathy. Jpn Circ J. 1998;62 (12):873–876.</mixed-citation><mixed-citation xml:lang="en">Kawakami H, Shigematsu Y, Ohtsuka T, Okayama H, Hayashi Y, Hara Y et al. Increased circulating soluble form of Fas in patients with dilated cardiomyopathy. Jpn Circ J. 1998;62 (12):873–876.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Niessner A, Hohensinner PJ, Rychli K, Neuhold S, Zorn G, Richter B et al. Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J. 2009;30(7): 789–796.</mixed-citation><mixed-citation xml:lang="en">Niessner A, Hohensinner PJ, Rychli K, Neuhold S,  Zorn G, Richter B et al. Prognostic value of apoptosis markers in advanced heart failure patients. Eur Heart J. 2009;30(7): 789–796.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T et al. Relationship between plasma levels of cardiac natriuretic peptides and soluble Fas: plasma soluble Fas as a prognostic predictor in patients with congestive heart failure. J Card Fail. 2001;7(4):322–328.</mixed-citation><mixed-citation xml:lang="en">Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T et al. Relationship between plasma levels of cardiac natriuretic peptides and soluble Fas: plasma soluble Fas as a prognostic predictor in patients with congestive heart failure. J Card Fail. 2001;7(4):322–328.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Mukherjee R, Brinsa TA, Dowdy KB, Scott AA, Baskin JM, Deschamps AM et al. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation. 2003;107(4):618–625.</mixed-citation><mixed-citation xml:lang="en">Mukherjee R, Brinsa TA, Dowdy KB, Scott AA, Baskin JM, Deschamps AM et al. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation. 2003;107(4):618–625.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res. 2012;110(1):159–173. doi:10.1161/ CIRCRESAHA.111.243162</mixed-citation><mixed-citation xml:lang="en">Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circ Res. 2012;110(1):159–173. doi:10.1161/ CIRCRESAHA.111.243162</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Mukherjee R, Mingoia JT, Bruce JA, Austin JS, Stroud RE, Escobar GP et al. Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction. Am J Physiol Heart Circ Physiol. 2006;291(5): H2216–2228. doi:10.1152/ajpheart.01343.2005</mixed-citation><mixed-citation xml:lang="en">Mukherjee R, Mingoia JT, Bruce JA, Austin JS, Stroud RE, Escobar GP et al. Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction. Am J Physiol Heart Circ Physiol. 2006;291(5): H2216–2228. doi:10.1152/ajpheart.01343.2005</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Soejima H, Ogawa H, Sakamoto T, Miyamoto S, Kajiwara I, Kojima S et al. Increased serum matrix metalloproteinase-1 concentration predicts advanced left ventricular remodeling in patients with acute myocardial infarction. Circ J. 2003;67(4):301– 304.</mixed-citation><mixed-citation xml:lang="en">Soejima H, Ogawa H, Sakamoto T, Miyamoto S, Kajiwara I, Kojima S et al. Increased serum matrix metalloproteinase-1 concentration predicts advanced left ventricular remodeling in patients with acute myocardial infarction. Circ J. 2003;67(4):301– 304.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Manhenke C, Orn S, Squire I, Radauceanu A, Alla F, Zannad F et al. The prognostic value of circulating markers of collagen turnover after acute myocardial infarction. Int J Cardiol. 2010;150(3):277–282.</mixed-citation><mixed-citation xml:lang="en">Manhenke C, Orn S, Squire I, Radauceanu A, Alla F, Zannad F et al. The prognostic value of circulating markers of collagen turnover after acute myocardial infarction. Int J Cardiol. 2010;150(3):277–282.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Kelly D, Khan S, Cockerill G, Ng LL, Thompson M, Samani NJ et al. Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction. Eur J Heart Fail. 2008;10 (2):133–139.</mixed-citation><mixed-citation xml:lang="en">Kelly D, Khan S, Cockerill G, Ng LL, Thompson M, Samani NJ et al. Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction. Eur J Heart Fail. 2008;10 (2):133–139.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Karpinski L, Plaksej R, Kosmala W, Witkowska M. Serum levels of interleukin-6, interleukin-10 and C-reactive protein in relation to left ventricular function in patients with myocardial infarction treated with primary angioplasty. Kardiol Pol. 2008;66(12): 12791285.</mixed-citation><mixed-citation xml:lang="en">Karpinski L, Plaksej R, Kosmala W, Witkowska M. Serum levels of interleukin-6, interleukin-10 and C-reactive protein in relation to left ventricular function in patients with myocardial infarction treated with primary angioplasty. Kardiol Pol. 2008;66(12): 12791285.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Van Kimmenade RR, Januzzi JL, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP, Pinto YM. Utility of amino-terminal probrain natriuretic peptide, galectin-3 and apelin for the evavaluation of patients with acute heart failure. J Am Coll Cardiol. 2006;48(6):1217– 24. Epub 2006 Aug 28.</mixed-citation><mixed-citation xml:lang="en">Van Kimmenade RR, Januzzi JL, Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP, Pinto YM. Utility of amino-terminal probrain natriuretic peptide, galectin-3 and apelin for the evavaluation of patients with acute heart failure. J Am Coll Cardiol. 2006;48(6):1217– 24. Epub 2006 Aug 28.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010;99(5):323– 328.</mixed-citation><mixed-citation xml:lang="en">Lok DJ, Van Der Meer P, de la Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010;99(5):323– 328.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ho JE, Yin X, Levy D, Vasan RS, Magnani JW, Ellinor PT et al. Galectin 3 and incident atrial fibrillation in the community. Am Heart J. 2014;167(5):729–734.</mixed-citation><mixed-citation xml:lang="en">Ho JE, Yin X, Levy D, Vasan RS, Magnani JW, Ellinor PT et al. Galectin 3 and incident atrial fibrillation in the community. Am Heart J. 2014;167(5):729–734.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Ionin VA, Zaslavskaya EL, Soboleva AV, Belyaeva OD, Baranova EI, Shlyakhto EV. Can we predict the effect of antiarrythmic pharmacotherapy in atrial fibrillation and metabolic syndrome patients: focus on galectin-3. Eur Heart J. 2016;37 (Supp.):881.</mixed-citation><mixed-citation xml:lang="en">Ionin VA, Zaslavskaya EL, Soboleva AV, Belyaeva OD, Baranova EI, Shlyakhto EV. Can we predict the effect of antiarrythmic pharmacotherapy in atrial fibrillation and metabolic syndrome patients: focus on galectin-3. Eur Heart J. 2016;37 (Supp.):881.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Медведева Е. А. Биомаркеры фиброза, почечной дисфункции и воспаления, их корреляционные взаимосвязи у пациентов с хронической сердечной недостаточностью ишемической этиологии. Сердечная недостаточность. 2017;18(2): 83–86. doi:10.18087/rhfj.2017.2.2302 [Medvedeva EA. Biomarkers of fibrosis, renal dysfunction and inflammation, and their correlations in ischemic heart failure. Journal Heart Failure. 2017;18(2):83–86. doi:10.18087/rhfj.2017.2.2302 In Russian].</mixed-citation><mixed-citation xml:lang="en">Медведева Е. А. Биомаркеры фиброза, почечной дисфункции и воспаления, их корреляционные взаимосвязи у пациентов с хронической сердечной недостаточностью ишемической этиологии. Сердечная недостаточность. 2017;18(2): 83–86. doi:10.18087/rhfj.2017.2.2302 [Medvedeva EA. Biomarkers of fibrosis, renal dysfunction and inflammation, and their correlations in ischemic heart failure. Journal Heart Failure. 2017;18(2):83–86. doi:10.18087/rhfj.2017.2.2302 In Russian].</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010;55(3):243–250.</mixed-citation><mixed-citation xml:lang="en">Weir RA, Miller AM, Murphy GE, Clements S, Steedman T, Connell JM et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J Am Coll Cardiol. 2010;55(3):243–250.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Januzzi JL, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (ProBrain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol. 2007;50(7):607–613.</mixed-citation><mixed-citation xml:lang="en">Januzzi JL, Peacock WF, Maisel AS, Chae CU, Jesse RL, Baggish AL et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (ProBrain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol. 2007;50(7):607–613.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Manzano-Fernandez S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL et al. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol. 2011;107(2):259–267.</mixed-citation><mixed-citation xml:lang="en">Manzano-Fernandez S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL et al. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol. 2011;107(2):259–267.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Boisot S, Beede J, Isakson S, Chiu A, Clopton P, Januzzi J et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail. 2008;14(9):732–738.</mixed-citation><mixed-citation xml:lang="en">Boisot S, Beede J, Isakson S, Chiu A, Clopton P, Januzzi J et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail. 2008;14(9):732–738.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Rehman SU, Martinez-Rumayor A, Mueller T, Januzzi JL. Independent and incremental prognostic value of multimarker testing in acute dyspnea: results from the ProBNP 21 Investigation of Dyspnea in the Emergency Department (PRIDE) study. Clin Chim Acta. 2008;392(1–2):41–45.</mixed-citation><mixed-citation xml:lang="en">Rehman SU, Martinez-Rumayor A, Mueller T, Januzzi JL. Independent and incremental prognostic value of multimarker testing in acute dyspnea: results from the ProBNP 21 Investigation of Dyspnea in the Emergency Department (PRIDE) study. Clin Chim Acta. 2008;392(1–2):41–45.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Протасов В. Н., Скворцов А. А., Нарусов О. Ю., Кошкина Д. Е., Ткачев Г. А., Горюнова Т. В. и др. Изменение концентрации растворимого ST2-рецептора за время госпитализации и прогноз больных декомпенсированной сердечной недостаточностью. Сердечная недостаточность. 2017;18(4):279–289. doi:10.18087/rhfj.2017.4.2370. [Protasov VN, Skvortsov AA, Naruso OYu, Koshkina DE, Tkachev GA, Goryunova TV et al. Changes in the concentration of ST2-receptor during hospita- lization and prognosis in patients with heart failure decompensation. Journal Heart Failure. 2017;18(4):279–289. doi:10.18087/rhfj.2017.4.2370. In Russian].</mixed-citation><mixed-citation xml:lang="en">Протасов В. Н., Скворцов А. А., Нарусов О. Ю., Кошкина Д. Е., Ткачев Г. А., Горюнова Т. В. и др. Изменение концентрации растворимого ST2-рецептора за время госпитализации и прогноз больных декомпенсированной сердечной недостаточностью. Сердечная недостаточность. 2017;18(4):279–289. doi:10.18087/rhfj.2017.4.2370. [Protasov VN, Skvortsov AA, Naruso OYu, Koshkina DE, Tkachev GA, Goryunova TV et al. Changes in the concentration of ST2-receptor during hospita- lization and prognosis in patients with heart failure decompensation. Journal Heart Failure. 2017;18(4):279–289. doi:10.18087/rhfj.2017.4.2370. In Russian].</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342 (18):1350–1358.</mixed-citation><mixed-citation xml:lang="en">Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342 (18):1350–1358.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Sun Y, Weber KT. Infarct scar: a dynamic tissue. Cardiovasc Res. 2000;46(2):250–256.</mixed-citation><mixed-citation xml:lang="en">Sun Y, Weber KT. Infarct scar: a dynamic tissue. Cardiovasc Res. 2000;46(2):250–256.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Agarwal I, Glazer NL, Barasch E, Biggs ML, Djousse L, Fitzpatrick AL et al. Fibrosis-related biomarkers and incident cardiovascular disease in older adults: the cardiovascular health study. Circ Arrhythm Electrophysiol. 2014;7(4):583–589.</mixed-citation><mixed-citation xml:lang="en">Agarwal I, Glazer NL, Barasch E, Biggs ML, Djousse L, Fitzpatrick AL et al. Fibrosis-related biomarkers and incident cardiovascular disease in older adults: the cardiovascular health study. Circ Arrhythm Electrophysiol. 2014;7(4):583–589.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Dixon DL, Griggs KM, Bersten AD, De Pasquale CG. Systemic inflammation and cell activation reflects morbidity in chronic heart failure. Cytokine. 2011;56(3):593–599.</mixed-citation><mixed-citation xml:lang="en">Dixon DL, Griggs KM, Bersten AD, De Pasquale CG. Systemic inflammation and cell activation reflects morbidity in chronic heart failure. Cytokine. 2011;56(3):593–599.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Francia P, Balla C, Ricotta A, Uccellini A, Frattari A, Modestino A et al. Plasma osteopontin reveals left ventricular reverse remodelling following cardiac resynchronization therapy in heart failure. Int J Cardiol. 2011;153(3):306–310.</mixed-citation><mixed-citation xml:lang="en">Francia P, Balla C, Ricotta A, Uccellini A, Frattari A, Modestino A et al. Plasma osteopontin reveals left ventricular reverse remodelling following cardiac resynchronization therapy in heart failure. Int J Cardiol. 2011;153(3):306–310.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
